Myriad Genetics targets LabCorp with BRCA patent suit

This didn't take long. Myriad Genetics' ($MYGN) attorneys have struck again and filed a suit this time against LabCorp ($LH), barely two days after it launched a series of predictive cancer diagnostic tests focused on BRCA mutations. Genome Web reported that Myriad accuses LabCorp of violating 11 U.S. patents involving its tests that cover BRCA1 and BRCA2 mutations. Myriad has dominated the market, but the U.S. Supreme Court opened the door to competition over the summer with a ruling that invalidated some of its patents but upheld others. With LabCorp's entry into the space, there are now seven rivals marketing tests focused on BRCA mutations, and Myriad is suing all of them. Story (sub. req.)

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Hand-held ultrasound developer Butterfly Network is going public through a $1.5 billion acquisition deal backed by Glenview Capital.